Feedback / Questions
AV-203 - AVEO, CANbridge Life Sciences
AVEO Oncology: Corporate Presentation
(Aveo Oncology)
-
Aug 13, 2015 -
Anticipated patent expiry for composition of matter in 2031; Anticipated patent expiry for NRG-1 biomarker in 2032
Anticipated patent expiry
•
Oncology
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
Aug 13, 2015
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.